A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
Condition(s):LymphangioleiomyomatosisLast Updated:September 28, 2022Completed
Hide Studies Not Open or Pending
Condition(s):LymphangioleiomyomatosisLast Updated:September 28, 2022Completed
Condition(s):Pulmonary LymphangioleiomyomatosisLast Updated:July 30, 2020Terminated
Condition(s):Lymphangioleiomyomatosis (LAM)Last Updated:January 20, 2022Completed
Condition(s):LymphangioleiomyomatosisLast Updated:January 13, 2022Recruiting
Condition(s):Pulmonary LymphangioleiomyomatosisLast Updated:November 30, 2016Completed
Condition(s):LymphangioleiomyomatosisLast Updated:December 11, 2015Completed
Condition(s):LymphangioleiomyomatosisLast Updated:March 22, 2024Recruiting
Condition(s):LymphangioleiomyomatosisLast Updated:October 11, 2018Completed
Condition(s):LymphangioleiomyomatosisLast Updated:March 26, 2024Recruiting
Condition(s):LymphangioleiomyomatosisLast Updated:February 22, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.